Home menu open
30th and final George Knudson Oakdale Pro-Am

Contact Us

Founded in 1926, Oakdale Golf & Country Club is widely recognized as one of Canada’s finest private golf and country clubs. Oakdale’s membership community enjoys a world class 27 hole championship golf course, beautiful clubhouse and exquisite dining facilities. Oakdale’s Stanley Thompson designed golf course provides a timeless setting that allows members to share their passion for golf with friends, family and guests. Inside the clubhouse, members are welcomed into a friendly atmosphere with casual and elegant dining prepared by an outstanding culinary team. As a community, Oakdale is committed to respecting its social responsibilities, charitable obligations and tradition of excellence.

Cathy Andreacola, Executive Assistant 416-245-3500 ext. 247

Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute, part of Sinai Health System, ranks among the world’s top 10 institutes of its kind. It is internationally esteemed for producing work with an enormous impact on the international scientific community. Lunenfeld-Tanenbaum scientists collaborate with Mount Sinai Hospital clinicians to build bridges between the latest research findings and pioneer the newest modalities of diagnosis and treatment, improving outcomes for patients. Their investigations are creating a healthier future for us all. Funds from the George Knudson Oakdale Pro-AM have supported cancer research at Mount Sinai. Starting in 2016, funds from the event will be used to establish an Endowed Scientist Chair in cancer research. An endowed chair will enable researchers to continue to make discoveries that improve the lives of people with cancer.

Charlene Spiteri, Manager, Community Events 416-586-4800 x 5155

Sinai Health Foundation Charitable Registration No. 119048106 RR0001


Israel Cancer Research Fund’s (ICRF) mission is to continue to find treatments and cures for all forms of cancer utilizing the unique benefits that Israel and its scientists have to offer. ICRF is one of the largest sources of private funds for innovative cancer research in Israel, funding over 2,200 grants to date. These grants resulted in the development of Gleevec®, a drug used in the treatment of leukemia, and Velcade®, a drug developed based on Nobel Prize winning research by ICRF funded scientists and used in the treatment of multiple myeloma. These are just two examples of ICRF breakthroughs that are helping save the lives of cancer patients worldwide.

Jennifer Ouaknine, Executive Director 416-480-9138

Israel Cancer Research Fund Charitable Registration No. 816102347 RR0001